甲状腺滤泡癌患者的颈部超声检查。

IF 3 4区 医学 Q3 Biochemistry, Genetics and Molecular Biology
Hormones & Cancer Pub Date : 2018-12-01 Epub Date: 2018-08-07 DOI:10.1007/s12672-018-0345-6
Konstantinos Segkos, Kyle Porter, Leigha Senter, Matthew D Ringel, Fadi A Nabhan
{"title":"甲状腺滤泡癌患者的颈部超声检查。","authors":"Konstantinos Segkos,&nbsp;Kyle Porter,&nbsp;Leigha Senter,&nbsp;Matthew D Ringel,&nbsp;Fadi A Nabhan","doi":"10.1007/s12672-018-0345-6","DOIUrl":null,"url":null,"abstract":"<p><p>There are limited data on the role of neck ultrasound (US) in the surveillance of patients with follicular thyroid cancer (FTC). Here, we analyze the likelihood of US to find structural disease in patients with FTC and evaluate if initial American Thyroid Association (ATA) risk stratification and the response to therapy categories [the latter based on thyroglobulin (Tg) levels] modify that likelihood. We conducted a retrospective cohort study of 32 patients with FTC in our institution. We included all patients with well-differentiated FTC who underwent total thyroidectomy and radioactive iodine (RAI) treatment without neck structural disease at the time of RAI and with Tg and US at least 6 months after RAI. After a median follow-up of 4.3 years, two patients (6.3%) had structural disease by US. None of the 18 patients with initial ATA low-risk disease had structural disease by US in contrast to higher, but not significant, frequency of 18.2% (2/11) in patients with initial ATA high-risk disease (p = 0.14). Based on Tg levels, 24/32 patients had excellent response to therapy and 8/32 had biochemical incomplete/indeterminate response. None of the patients with excellent response had structural disease by US versus 2/8 (25%) patients with biochemical incomplete/indeterminate response all of whom had other sites of structural disease (p = 0.054). Our findings suggest that neck US in FTC is unlikely to find structural disease with initial low-risk ATA or excellent response to therapy but can detect structural disease in some patients with initial ATA high-risk or incomplete/indeterminate responses to therapy.</p>","PeriodicalId":13060,"journal":{"name":"Hormones & Cancer","volume":" ","pages":"433-439"},"PeriodicalIF":3.0000,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12672-018-0345-6","citationCount":"9","resultStr":"{\"title\":\"Neck Ultrasound in Patients with Follicular Thyroid Carcinoma.\",\"authors\":\"Konstantinos Segkos,&nbsp;Kyle Porter,&nbsp;Leigha Senter,&nbsp;Matthew D Ringel,&nbsp;Fadi A Nabhan\",\"doi\":\"10.1007/s12672-018-0345-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>There are limited data on the role of neck ultrasound (US) in the surveillance of patients with follicular thyroid cancer (FTC). Here, we analyze the likelihood of US to find structural disease in patients with FTC and evaluate if initial American Thyroid Association (ATA) risk stratification and the response to therapy categories [the latter based on thyroglobulin (Tg) levels] modify that likelihood. We conducted a retrospective cohort study of 32 patients with FTC in our institution. We included all patients with well-differentiated FTC who underwent total thyroidectomy and radioactive iodine (RAI) treatment without neck structural disease at the time of RAI and with Tg and US at least 6 months after RAI. After a median follow-up of 4.3 years, two patients (6.3%) had structural disease by US. None of the 18 patients with initial ATA low-risk disease had structural disease by US in contrast to higher, but not significant, frequency of 18.2% (2/11) in patients with initial ATA high-risk disease (p = 0.14). Based on Tg levels, 24/32 patients had excellent response to therapy and 8/32 had biochemical incomplete/indeterminate response. None of the patients with excellent response had structural disease by US versus 2/8 (25%) patients with biochemical incomplete/indeterminate response all of whom had other sites of structural disease (p = 0.054). Our findings suggest that neck US in FTC is unlikely to find structural disease with initial low-risk ATA or excellent response to therapy but can detect structural disease in some patients with initial ATA high-risk or incomplete/indeterminate responses to therapy.</p>\",\"PeriodicalId\":13060,\"journal\":{\"name\":\"Hormones & Cancer\",\"volume\":\" \",\"pages\":\"433-439\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2018-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1007/s12672-018-0345-6\",\"citationCount\":\"9\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hormones & Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12672-018-0345-6\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2018/8/7 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"Biochemistry, Genetics and Molecular Biology\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hormones & Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12672-018-0345-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/8/7 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 9

摘要

关于颈部超声(US)在监测滤泡性甲状腺癌(FTC)患者中的作用的数据有限。在这里,我们分析了美国在FTC患者中发现结构性疾病的可能性,并评估了最初的美国甲状腺协会(ATA)风险分层和对治疗类别的反应(后者基于甲状腺球蛋白(Tg)水平)是否改变了这种可能性。我们对我院32例FTC患者进行了回顾性队列研究。我们纳入了所有接受甲状腺全切除术和放射性碘(RAI)治疗的高分化FTC患者,这些患者在RAI时没有颈部结构性疾病,并且在RAI后至少6个月接受Tg和US治疗。中位随访4.3年后,2例患者(6.3%)出现结构性疾病。18例初始ATA低危性疾病患者均无结构性疾病,而初始ATA高危性疾病患者的US频率较高,为18.2%(2/11),但不显著(p = 0.14)。根据Tg水平,24/32例患者对治疗反应极好,8/32例患者生化反应不完全/不确定。在US标准下,反应优异的患者均无结构性疾病,而2/8(25%)生化反应不完全/不确定的患者均有其他部位的结构性疾病(p = 0.054)。我们的研究结果表明,FTC颈部US不太可能发现初始低风险ATA或对治疗反应良好的结构性疾病,但可以在一些初始ATA高风险或对治疗反应不完全/不确定的患者中发现结构性疾病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Neck Ultrasound in Patients with Follicular Thyroid Carcinoma.

Neck Ultrasound in Patients with Follicular Thyroid Carcinoma.

Neck Ultrasound in Patients with Follicular Thyroid Carcinoma.

There are limited data on the role of neck ultrasound (US) in the surveillance of patients with follicular thyroid cancer (FTC). Here, we analyze the likelihood of US to find structural disease in patients with FTC and evaluate if initial American Thyroid Association (ATA) risk stratification and the response to therapy categories [the latter based on thyroglobulin (Tg) levels] modify that likelihood. We conducted a retrospective cohort study of 32 patients with FTC in our institution. We included all patients with well-differentiated FTC who underwent total thyroidectomy and radioactive iodine (RAI) treatment without neck structural disease at the time of RAI and with Tg and US at least 6 months after RAI. After a median follow-up of 4.3 years, two patients (6.3%) had structural disease by US. None of the 18 patients with initial ATA low-risk disease had structural disease by US in contrast to higher, but not significant, frequency of 18.2% (2/11) in patients with initial ATA high-risk disease (p = 0.14). Based on Tg levels, 24/32 patients had excellent response to therapy and 8/32 had biochemical incomplete/indeterminate response. None of the patients with excellent response had structural disease by US versus 2/8 (25%) patients with biochemical incomplete/indeterminate response all of whom had other sites of structural disease (p = 0.054). Our findings suggest that neck US in FTC is unlikely to find structural disease with initial low-risk ATA or excellent response to therapy but can detect structural disease in some patients with initial ATA high-risk or incomplete/indeterminate responses to therapy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Hormones & Cancer
Hormones & Cancer ONCOLOGY-ENDOCRINOLOGY & METABOLISM
CiteScore
4.60
自引率
0.00%
发文量
0
期刊介绍: Hormones and Cancer is a unique multidisciplinary translational journal featuring basic science, pre-clinical, epidemiological, and clinical research papers. It covers all aspects of the interface of Endocrinology and Oncology. Thus, the journal covers two main areas of research: Endocrine tumors (benign & malignant tumors of hormone secreting endocrine organs) and the effects of hormones on any type of tumor. We welcome all types of studies related to these fields, but our particular attention is on translational aspects of research. In addition to basic, pre-clinical, and epidemiological studies, we encourage submission of clinical studies including those that comprise small series of tumors in rare endocrine neoplasias and/or negative or confirmatory results provided that they significantly enhance our understanding of endocrine aspects of oncology. The journal does not publish case studies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信